Ligufalimab (CD47)-Based Combination Shows Promising Results in Frontline AML Treatment
Recent Phase II trial results presented at EHA 2026 highlight the effectiveness of Ligufalimab-based therapies in treating frontline acute myeloid leukemia (AML). The combination therapy demonstrates significant survival benefits and deep responses among patients.